In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares closed today at $3.20.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Cardiff Oncology, and Puma Biotechnology. According to TipRanks, Frahm has an average return of 11.0% and a 43.55% success rate on recommended stocks.
Currently, the analyst consensus on Inozyme Pharma is a Strong Buy with an average price target of $16.00.
See the top stocks recommended by analysts >>
Based on Inozyme Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.58 million. In comparison, last year the company had a GAAP net loss of $15.26 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inozyme Pharma (INZY) Company Description:
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Read More on INZY:
- Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme highlights inclusion of GACI in Genomics England’s Generation Study
- Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
- Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
